Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma.

esthesioneuroblastoma induction neoadjuvant outcomes therapy

Journal

Journal of neurological surgery. Part B, Skull base
ISSN: 2193-6331
Titre abrégé: J Neurol Surg B Skull Base
Pays: Germany
ID NLM: 101580780

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 10 06 2019
accepted: 12 11 2019
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 27 7 2021
Statut: ppublish

Résumé

Esthesioneuroblastoma (ENB) is a rare olfactory malignancy that can present with locally advanced disease. At our institution, patients with ENB in whom the treating surgeon believes that a margin-negative resection is initially not achievable are selected to undergo induction with chemotherapy with or without radiotherapy prior to surgery. In a retrospective review of 61 patient records, we identified six patients (10%) treated with this approach. Five of six patients (83%) went on to definitive surgery. Prior to surgery, three of five patients (60%) had a partial response after induction therapy, whereas two of five (40%) had stable disease. Microscopically margin-negative resection was achieved in four of five (80%) of the patients who went on to surgery, while one patient had negative margins on frozen section but microscopically positive margins on permanent section. Three of five patients (60%) recurred after surgery; two of these patients died with recurrent/metastatic ENB. In summary, induction therapy may facilitate margin-negative resection in locally advanced ENB. Given the apparent sensitivity of ENB to chemotherapy and radiotherapy, future prospective studies should investigate the optimal multidisciplinary approach to improve long-term survival in this rare disease.

Identifiants

pubmed: 34306928
doi: 10.1055/s-0039-3402026
pii: 190177
pmc: PMC8289526
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e131-e137

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest A.V.C. reports funding for clinical trials from Merck, AstraZeneca/MedImmune, Kura Oncology, Inovio, Eisai (all institutional). The other authors report no relevant conflict of interest in submitting this article for publication.

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Neurol Surg B Skull Base. 2012 Oct;73(5):331-6
pubmed: 24083125
Head Neck. 2005 Feb;27(2):138-49
pubmed: 15654688
Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8
pubmed: 9588546
Head Neck. 2019 May;41(5):1335-1341
pubmed: 30536472
J Pediatr Hematol Oncol. 2014 Mar;36(2):91-5
pubmed: 24390450
Cancer. 2008 Feb 15;112(4):885-91
pubmed: 18189294
J Clin Oncol. 2019 Feb 20;37(6):504-512
pubmed: 30615549
Laryngoscope. 1992 Aug;102(8):843-9
pubmed: 1495347
Lancet Oncol. 2001 Nov;2(11):683-90
pubmed: 11902539
Cancer. 2004 Nov 15;101(10):2257-60
pubmed: 15484215
J Neurol Surg B Skull Base. 2015 Feb;76(1):43-9
pubmed: 25685649
Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40
pubmed: 9006501
Neurosurgery. 1993 May;32(5):706-14; discussion 714-5
pubmed: 8492845
Oncotarget. 2016 Aug 9;7(32):52584-52596
pubmed: 27256979
J Neurol Surg B Skull Base. 2018 Oct;79(5):495-500
pubmed: 30210978
Cancer. 2002 May 15;94(10):2623-34
pubmed: 12173330
Cancer. 1994 May 15;73(10):2556-62
pubmed: 8174053
Anticancer Res. 1997 Jul-Aug;17(4A):2683-706
pubmed: 9252701
J Neurooncol. 2008 Nov;90(2):201-4
pubmed: 18633576
Int J Surg Oncol. 2016;2016:6923730
pubmed: 26955484
Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8
pubmed: 16490869
Acta Otolaryngol. 2003 Apr;123(3):433-9
pubmed: 12737303
Cancer Discov. 2019 Mar;9(3):354-369
pubmed: 30518523

Auteurs

Kevin C Miller (KC)

Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, United States.

John P Marinelli (JP)

Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, United States.

Jeffrey R Janus (JR)

Department of Otolaryngology Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.

Ashish V Chintakuntlawar (AV)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, United States.

Robert L Foote (RL)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, United States.

Michael J Link (MJ)

Department of Otolaryngology Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States.

Garret Choby (G)

Department of Otolaryngology Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.

Jamie J Van Gompel (JJ)

Department of Otolaryngology Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States.

Classifications MeSH